Lung cancer is the most common cause of cancer-related death, worldwide. Historically,
lung cancer has been divided into two main histological types: small cell and nonsmall cell
(NSC) type with the latter being subdivided into adenocarcinoma, squamous cell type, and
large cell type. The treatment of the NSC lung cancer (NSCLC), especially the
adenocarcinoma subtype, has been transformed in the last decade by the availability of
predictive biomarkers for molecularly targeted therapies. Currently, for patients with …